HRTX - HERON THERAPEUTICS, INC. /DE/
IEX Last Trade
1.52
-0.015 -0.987%
Share volume: 9,181
Last Updated: Fri 27 Dec 2024 05:29:49 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$1.54
-0.02
-0.98%
Fundamental analysis
24%
Profitability
25%
Dept financing
7%
Liquidity
66%
Performance
16%
Performance
5 Days
-1.25%
1 Month
43.64%
3 Months
-22.93%
6 Months
-52.55%
1 Year
-10.73%
2 Year
-38.52%
Key data
Stock price
$1.52
DAY RANGE
$1.53 - $1.62
52 WEEK RANGE
$1.10 - $3.93
52 WEEK CHANGE
-$9.20
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Barry D. Quart
Region: US
Website: herontx.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: herontx.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Heron Therapeutics, Inc. engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy.
Recent news